
1. NPJ Vaccines. 2021 Oct 22;6(1):123. doi: 10.1038/s41541-021-00385-6.

A recombinant measles virus vaccine strongly reduces SHIV viremia and virus
reservoir establishment in macaques.

Nzounza P(#)(1)(2)(3), Martin G(#)(3), Dereuddre-Bosquet N(4), Najburg V(5),
Gosse L(4), Ruffié C(5), Combredet C(5), Petitdemange C(3), Souquère S(1)(2),
Schlecht-Louf G(6), Moog C(7), Pierron G(1)(2), Le Grand R(4), Heidmann
T(#)(8)(9), Tangy F(#)(10).

Author information: 
(1)Molecular Physiology and Pathology of Endogenous and Infectious Retroviruses
Unit, CNRS UMR 9196, Gustave Roussy, Villejuif, France.
(2)UMR 9196, Université Paris-Sud, Orsay, France.
(3)VIROxIS, Gustave Roussy, Villejuif, France.
(4)Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department,
IBJF, CEA-Université Paris-Sud-INSERM U1184, Fontenay-Aux-Roses, France.
(5)Viral Genomics and Vaccination Unit, Department of Virology, Institut Pasteur,
CNRS UMR 3965, Paris, France.
(6)UMR996-Inflammation, Chimiokines et Immunopathologie, INSERM, Faculté de
médecine, Université Paris-Sud, Université Paris-Saclay, Clamart, France.
(7)INSERM U1109, Fédération de Médecine Translationnelle de Strasbourg (FMTS),
Université de Strasbourg, Strasbourg, France.
(8)Molecular Physiology and Pathology of Endogenous and Infectious Retroviruses
Unit, CNRS UMR 9196, Gustave Roussy, Villejuif, France.
thierry.heidmann@gustaveroussy.fr.
(9)UMR 9196, Université Paris-Sud, Orsay, France.
thierry.heidmann@gustaveroussy.fr.
(10)Viral Genomics and Vaccination Unit, Department of Virology, Institut
Pasteur, CNRS UMR 3965, Paris, France. ftangy@pasteur.fr.
(#)Contributed equally

Replicative vectors derived from live-attenuated measles virus (MV) carrying
additional non-measles vaccine antigens have long demonstrated safety and
immunogenicity in humans despite pre-existing immunity to measles. Here, we
report the vaccination of cynomolgus macaques with MV replicative vectors
expressing simian-human immunodeficiency virus Gag, Env, and Nef antigens
(MV-SHIV Wt) either wild type or mutated in the immunosuppressive (IS) domains of
Nef and Env antigens (MV-SHIV Mt). We found that the inactivation of Nef and Env 
IS domains by targeted mutations led to the induction of significantly enhanced
post-prime cellular immune responses. After repeated challenges with low doses of
SHIV-SF162p3, vaccinees were protected against high viremia, resulting in a 2-Log
reduction in peak viremia, accelerated viral clearance, and a decrease -even
complete protection for nearly half of the monkeys- in reservoir cell infection. 
This study demonstrates the potential of a replicative viral vector derived from 
the safe and widely used measles vaccine in the development of a future human
vaccine against HIV-1.

© 2021. The Author(s).

DOI: 10.1038/s41541-021-00385-6 
PMCID: PMC8536681
PMID: 34686669 

